Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment

Given the interconnection between depressive and cardiovascular disorders, we investigated whether antidepressant treatment (fluoxetine) modifies the serotonergic influence on rat vascular noradrenergic outflow. Twelve-week-old male Wistar rats received fluoxetine treatment (10 mg/kg/day; p.o.) for...

Full description

Bibliographic Details
Main Authors: José Ángel García-Pedraza, Cristina López, Juan Francisco Fernández-González, María Luisa Martín, Asunción Morán, Mónica García-Domingo
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Journal of Pharmacological Sciences
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861321000505
_version_ 1818453491865092096
author José Ángel García-Pedraza
Cristina López
Juan Francisco Fernández-González
María Luisa Martín
Asunción Morán
Mónica García-Domingo
author_facet José Ángel García-Pedraza
Cristina López
Juan Francisco Fernández-González
María Luisa Martín
Asunción Morán
Mónica García-Domingo
author_sort José Ángel García-Pedraza
collection DOAJ
description Given the interconnection between depressive and cardiovascular disorders, we investigated whether antidepressant treatment (fluoxetine) modifies the serotonergic influence on rat vascular noradrenergic outflow. Twelve-week-old male Wistar rats received fluoxetine treatment (10 mg/kg/day; p.o.) for 14 days; then, they were pithed and prepared for sympathetic stimulation. Vasopressor responses were obtained by electrical stimulation of the sympathetic outflow (0.1, 0.5, 1, and 5 Hz) or i.v. noradrenaline (NA; 0.01, 0.05, 0.1, and 0.5 μg/kg). In fluoxetine-treated group, the electrical-induced vasoconstrictions were lower compared to non-treated rats. Intravenous infusion of 5-HT (10 μg/kg/min) inhibited the sympathetically-induced vasoconstrictions. Only 5-CT, 8-OH-DPAT and L-694,247 (5-HT1/7, 5-HT1A and 5-HT1D agonists, respectively) mimicked 5-HT-induced inhibition, while α-methyl-5-HT (5-HT2 agonist) increased the vasopressor responses. The inhibitory effect of 5-HT was: a) no modified by SB269970 (5-HT7 antagonist); b) abolished by WAY-100,635 (5-HT1A antagonist) plus LY310762 (5-HT1D antagonist); and c) potentiated by ritanserin (5-HT2A receptor antagonist). The vasoconstrictions induced by exogenous NA were not modified by 5-CT but were increased by α-methyl-5-HT. Our results suggest that fluoxetine treatment decreases NA release at vascular level and changes 5-HT modulation on rat vascular noradrenergic neurotransmission, inducing sympatho-inhibition via prejunctional 5-HT1A/1D receptors, and sympatho-potentiation via pre and/or postjunctional 5-HT2A receptors.
first_indexed 2024-12-14T21:39:50Z
format Article
id doaj.art-85090b45d91a455c88f3ccb1b99c62c3
institution Directory Open Access Journal
issn 1347-8613
language English
last_indexed 2024-12-14T21:39:50Z
publishDate 2021-09-01
publisher Elsevier
record_format Article
series Journal of Pharmacological Sciences
spelling doaj.art-85090b45d91a455c88f3ccb1b99c62c32022-12-21T22:46:29ZengElsevierJournal of Pharmacological Sciences1347-86132021-09-0114714857Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatmentJosé Ángel García-Pedraza0Cristina López1Juan Francisco Fernández-González2María Luisa Martín3Asunción Morán4Mónica García-Domingo5Laboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, SpainLaboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain; Research Institute of Salamanca (IBSAL), Paseo San Vicente 58-182, 37007, Salamanca, Spain; Corresponding author. Laboratory of Pharmacology, Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain. Fax: +34 923 29 45 15.Given the interconnection between depressive and cardiovascular disorders, we investigated whether antidepressant treatment (fluoxetine) modifies the serotonergic influence on rat vascular noradrenergic outflow. Twelve-week-old male Wistar rats received fluoxetine treatment (10 mg/kg/day; p.o.) for 14 days; then, they were pithed and prepared for sympathetic stimulation. Vasopressor responses were obtained by electrical stimulation of the sympathetic outflow (0.1, 0.5, 1, and 5 Hz) or i.v. noradrenaline (NA; 0.01, 0.05, 0.1, and 0.5 μg/kg). In fluoxetine-treated group, the electrical-induced vasoconstrictions were lower compared to non-treated rats. Intravenous infusion of 5-HT (10 μg/kg/min) inhibited the sympathetically-induced vasoconstrictions. Only 5-CT, 8-OH-DPAT and L-694,247 (5-HT1/7, 5-HT1A and 5-HT1D agonists, respectively) mimicked 5-HT-induced inhibition, while α-methyl-5-HT (5-HT2 agonist) increased the vasopressor responses. The inhibitory effect of 5-HT was: a) no modified by SB269970 (5-HT7 antagonist); b) abolished by WAY-100,635 (5-HT1A antagonist) plus LY310762 (5-HT1D antagonist); and c) potentiated by ritanserin (5-HT2A receptor antagonist). The vasoconstrictions induced by exogenous NA were not modified by 5-CT but were increased by α-methyl-5-HT. Our results suggest that fluoxetine treatment decreases NA release at vascular level and changes 5-HT modulation on rat vascular noradrenergic neurotransmission, inducing sympatho-inhibition via prejunctional 5-HT1A/1D receptors, and sympatho-potentiation via pre and/or postjunctional 5-HT2A receptors.http://www.sciencedirect.com/science/article/pii/S13478613210005055-HTFluoxetineNoradrenalineSympathetic neurotransmissionVascular tone
spellingShingle José Ángel García-Pedraza
Cristina López
Juan Francisco Fernández-González
María Luisa Martín
Asunción Morán
Mónica García-Domingo
Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
Journal of Pharmacological Sciences
5-HT
Fluoxetine
Noradrenaline
Sympathetic neurotransmission
Vascular tone
title Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
title_full Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
title_fullStr Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
title_full_unstemmed Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
title_short Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
title_sort vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment
topic 5-HT
Fluoxetine
Noradrenaline
Sympathetic neurotransmission
Vascular tone
url http://www.sciencedirect.com/science/article/pii/S1347861321000505
work_keys_str_mv AT joseangelgarciapedraza vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment
AT cristinalopez vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment
AT juanfranciscofernandezgonzalez vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment
AT marialuisamartin vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment
AT asuncionmoran vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment
AT monicagarciadomingo vascularsympatheticneurotransmissionanditsserotonergicregulationaremodifiedbychronicfluoxetinetreatment